Cathie's Ark LogoCathie's Ark
BEGIN TYPING TO SEARCH BY TICKER
Intellia Therapeutics Inc Logo

Combined Holdings of Intellia Therapeutics (NTLA) - Updated Daily

Maxinomics.com icon
YouTube Logo
Date
Direction
Shares
Fund Weight
Fund
September 19, 2022
BUY17.959k0.0427%ARKG
September 19, 2022
BUY52.914k0.0413%ARKK
September 16, 2022
BUY235.373k0.1727%ARKK
September 16, 2022
BUY83.502k0.1856%ARKG
August 3, 2022
SELL82.515k0.0621%ARKK

Key Statistics

🕵🏼Found In🏷Last Price
ARKKARKG$46.12
⚖️Weighting🧢Market Cap
2.97%$3.93b
🏋️‍♀️Weight Rank Across All Funds🧮Price to Sales
1076.48
💳ARK Estimated Cost Average🌏Country
$54.51 - ARKG$62.04 - ARKK
🇺🇸United States
🎫ARK Ownership Percent
11.04%
Description
Intellia Therapeutics is a leading clinical-stage genome editing company, focused on the development of proprietary, potentially curative therapeutics using the CRISPR/Cas9 system. Intellia believes the CRISPR/Cas9 technology has the potential to transform medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creating enhanced engineered cells that can treat oncological and immunological diseases. Intellia's combination of deep scientific, technical and clinical development experience, along with its leading intellectual property portfolio, puts it in a unique position to unlock broad therapeutic applications of the CRISPR/Cas9 technology and create new classes of therapeutic products.
Website
www.intelliatx.com